Sun Pharmaceutical Industries Ltd. reported financials for the first quarter ending June, 2013.
Dilip Shanghvi, Managing Director of the Company said, "All our businesses continue to perform in-line with our expectations.We remain focused on strengthening our existing businesses and developing a differentiated and speciality driven product basket. We also continue to review opportunities to expand and strengthen our global footprint."
Highlights of Q1FY14 consolidated financials:
- Branded generic sales in India, at Rs. 849 crores, grew by 44% over Q1 last year. Adjusted sales growth of the domestic formulation business.
- US finished dosages sale is US$ 364 million recording a growth of 28% over Q1 last year.